In addition to enhancing insulin secretion, binding to these receptors and downstream signaling slow gastric emptying and reduce appetite, leading to weight loss
Researchers used propensity score matching to match 9,193 adults using tirzepatide with 9,192 adults using semaglutide
Effects typically become more pronounced as the dose increases during the 16-week titration period, with peak appetite control often occurring around weeks 16-20 of treatment
Individual variation in GLP-1 receptor expression and gastrointestinal motility explains why one person tolerates a dose easily while another experiences significant symptoms at the same level
For urgent mental health support, contact NHS urgent mental health helplines, your GP, NHS 111, or go to A&E if in immediate danger